Befovacimab

Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI) . Befovacimab can be used for haemophilia A/B research[1].

Product Specifications

CAS Number

[2156634-62-5]

Product Name Alternative

BAY 1093884

UNSPSC

12352203

Target

Thrombin; Tissue Factor Pathway Inhibitor (TFPI)

Type

Inhibitory Antibodies

Related Pathways

Cytoskeleton; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/befovacimab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Befovacimab]

Molecular Weight

(142.98 kDa)

References & Citations

[1]Maria Elisa Mancuso, et al. Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis. Haemophilia. 2022 Sep;28 (5) :702-712. |[2]Jian-Ming Gu, et al. Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys. AAPS J. 2017 Jul;19 (4) :1186-1195.